Last updated: 2026-09-09 12:53:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Kestra Medical Technologies, Ltd (KMTS) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $25,66, with a market capitalisation of $1,50B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17,34 to $30,00. This page covers its latest market performance, valuation, price trends and company information.
$1,50B | |
$25,45 | |
$30,00 | |
$13,25 | |
$25,54 | |
309,21K | |
359,35K | |
-- | |
$30,00 | |
$17,34 | |
0,02% | |
-- |
Kestra Medical Technologies, Ltd (KMTS) is trading at $25,17 in pre-market trading as of 2026-09-08 23:31:00, down 1,47% ($0,38) from the previous close of $25,54
Pre-market trading shows how investors are pricing KMTS before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Kestra Medical Technologies, Ltd (KMTS) moved from $25,64 to $25,66, representing a gain of 0,07% ($0,02).
The stock traded between $24,76 and $26,50 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 257,05 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 65,7%
KMTS is currently trading at $25,66, placing it 65,7% of the way from its 52-week low of $17,34 to its 52-week high of $30,00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kestra Medical Technologies Ltd is a commercial-stage wearable medical device and digital healthcare company focused on connected monitoring, therapeutic intervention, and data-driven clinical insights for cardiovascular disease. It has developed and is commercializing the Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. The platform is anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected. The platform also includes digital patient engagement and clinical workflow solutions.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 443 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kestra Medical Technologies, Ltd (KMTS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.